{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T01:49:14Z","timestamp":1790300954470,"version":"4.1.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T00:00:00Z","timestamp":1678060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T00:00:00Z","timestamp":1678060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Chemistry"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Nonsteroidal anti-inflammatory drugs (NSAIDs) have been the most commonly used class of medications worldwide for the last three decades.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study aimed to design and synthesize a novel series of methoxyphenyl thiazole carboxamide derivatives and evaluate their cyclooxygenase (COX) suppressant and cytotoxic properties.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The synthesized compounds were characterized using\n                      <jats:sup>1<\/jats:sup>\n                      H,\n                      <jats:sup>13<\/jats:sup>\n                      C-NMR, IR, and HRMS spectrum analysis and were evaluated for their selectivity towards COX-1 and COX-2 using an in vitro COX inhibition assay kit. Besides, their cytotoxicity was evaluated using the Sulforhodamine B (SRB) assay. Moreover, molecular docking studies were conducted to identify the possible binding patterns of these compounds within both COX-1 and COX-2 isozymes, utilizing human X-ray crystal structures. The density functional theory (DFT) analysis was used to evaluate compound chemical reactivity, which was determined by calculating the frontier orbital energy of both HOMO and LUMO orbitals, as well as the HOMO\u2013LUMO energy gap. Finally, the QiKProp module was used for ADME-T analysis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The results revealed that all synthesized molecules have potent inhibitory activities against COX enzymes. The percentage of inhibitory activities at 5\u00a0\u00b5M concentration against the COX2 enzyme was in the range of 53.9\u201381.5%, while the percentage against the COX-1 enzyme was 14.7\u201374.8%. That means almost all of our compounds have selective inhibition activities against the COX-2 enzyme, and the most selective compound was\n                      <jats:bold>2f<\/jats:bold>\n                      , with selectivity ratio (SR) value of 3.67 at 5\u00a0\u00b5M concentration, which has a bulky group of trimethoxy on the phenyl ring that could not bind well with the COX-1 enzyme. Compound\n                      <jats:bold>2h<\/jats:bold>\n                      was the most potent, with an inhibitory activity percentage at 5\u00a0\u00b5M concentration of 81.5 and 58.2% against COX-2 and COX-1, respectively. The cytotoxicity of these compounds was evaluated against three cancer cell lines: Huh7, MCF-7, and HCT116, and negligible or very weak activities were observed for all of these compounds except compound\n                      <jats:bold>2f,<\/jats:bold>\n                      which showed moderate activities with IC\n                      <jats:sub>50<\/jats:sub>\n                      values of 17.47 and 14.57\u00a0\u00b5M against Huh7 and HCT116 cancer cell lines, respectively. Analysis of the molecular docking suggests\n                      <jats:bold>2d<\/jats:bold>\n                      ,\n                      <jats:bold>2e<\/jats:bold>\n                      ,\n                      <jats:bold>2f<\/jats:bold>\n                      , and\n                      <jats:bold>2i<\/jats:bold>\n                      molecules were bound to COX-2 isozyme favorably over COX-1 enzyme, and their interaction behaviors within COX-1 and COX-2 isozymes were comparable to celecoxib, as an ideal selective COX-2 drug, which explained their high potency and COX-2 selectivity. The molecular docking scores and expected affinity using the MM-GBSA approach were consistent with the recorded biological activity. The calculated global reactivity descriptors, such as HOMO and LUMO energies and the HOMO\u2013LUMO gaps, confirmed the key structural features required to achieve favorable binding interactions and thus improve affinity. The in silico ADME-T studies asserted the druggability of molecules and have the potential to become lead molecules in the drug discovery process.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      In general, the series of the synthesized compounds had a strong effect on both enzymes (COX-1 and COX-2) and the trimethoxy compound\n                      <jats:bold>2f<\/jats:bold>\n                      was more selective than the other compounds.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13065-023-00924-3","type":"journal-article","created":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T03:03:55Z","timestamp":1678071835000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Design, synthesis, molecular docking studies and biological evaluation of thiazole carboxamide derivatives as COX inhibitors"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5640-9700","authenticated-orcid":false,"given":"Mohammed","family":"Hawash","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nidal","family":"Jaradat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murad","family":"Abualhasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat Kad\u0131r","family":"\u015e\u00fck\u00fcro\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed T.","family":"Qaoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deniz Cansen","family":"Kahraman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heba","family":"Daraghmeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leen","family":"Maslamani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mais","family":"Sawafta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ala","family":"Ratrout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Issa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,6]]},"reference":[{"issue":"4","key":"924_CR1","first-page":"655","volume":"10","author":"A Zarghi","year":"2011","unstructured":"Zarghi A, Arfaei S. Selective COX-2 inhibitors: a review of their structure-activity relationships. Iran J Pharm Res IJPR. 2011;10(4):655\u201383.","journal-title":"Iran J Pharm Res IJPR"},{"issue":"11","key":"924_CR2","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/S0006-2952(01)00747-X","volume":"62","author":"S Fiorucci","year":"2001","unstructured":"Fiorucci S, Meli R, Bucci M, Cirino G. Dual inhibitors of cyclooxygenase and 5-lipoxygenase. A new avenue in anti-inflammatory therapy? Biochem Pharmacol. 2001;62(11):1433\u20138.","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"924_CR3","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.clim.2006.01.016","volume":"119","author":"JY Park","year":"2006","unstructured":"Park JY, Pillinger MH, Abramson SB. Prostaglandin E2 synthesis and secretion: the role of PGE2 synthases. Clin Immunol. 2006;119(3):229\u201340.","journal-title":"Clin Immunol"},{"issue":"10","key":"924_CR4","doi-asserted-by":"publisher","first-page":"5821","DOI":"10.1021\/cr2002992","volume":"111","author":"WL Smith","year":"2011","unstructured":"Smith WL, Urade Y, Jakobsson P-J. Enzymes of the cyclooxygenase pathways of prostanoid biosynthesis. Chem Rev. 2011;111(10):5821\u201365.","journal-title":"Chem Rev"},{"key":"924_CR5","first-page":"129","volume":"60","author":"F Burdan","year":"2006","unstructured":"Burdan F, Cha\u0142as A, Szumi\u0142o J. Cyklooksygenaza i prostanoidy\u2013znaczenie biologiczne* Cyclooxygenase and prostanoids\u2013biological implications. Postepy Hig Med Dosw. 2006;60:129\u201341.","journal-title":"Postepy Hig Med Dosw"},{"issue":"1","key":"924_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2105-11-1","volume":"11","author":"P Paragi-Vedanthi","year":"2010","unstructured":"Paragi-Vedanthi P, Doble M. Comparison of PGH2 binding site in prostaglandin synthases. BMC Bioinformatics. 2010;11(1):1\u20138.","journal-title":"BMC Bioinformatics"},{"issue":"5\u20136","key":"924_CR7","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0049-3848(03)00379-7","volume":"110","author":"J Vane","year":"2003","unstructured":"Vane J, Botting R. The mechanism of action of aspirin. Thromb Res. 2003;110(5\u20136):255\u20138.","journal-title":"Thromb Res"},{"issue":"9b","key":"924_CR8","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1111\/j.1582-4934.2008.00430.x","volume":"13","author":"N Zidar","year":"2009","unstructured":"Zidar N, Odar K, Glavac D, Jerse M, Zupanc T, Stajer D. Cyclooxygenase in normal human tissues\u2013is COX-1 really a constitutive isoform, and COX-2 an inducible isoform? J Cell Mol Med. 2009;13(9b):3753\u201363.","journal-title":"J Cell Mol Med"},{"issue":"31","key":"924_CR9","doi-asserted-by":"publisher","first-page":"2S","DOI":"10.1016\/S0002-9343(97)00203-9","volume":"104","author":"JR Vane","year":"1998","unstructured":"Vane JR, Botting RM. Mechanism of action of nonsteroidal anti-inflammatory drugs. Am J Med. 1998;104(31):2S-8S.","journal-title":"Am J Med"},{"issue":"23\u201324","key":"924_CR10","doi-asserted-by":"publisher","first-page":"3592","DOI":"10.1016\/j.bmcl.2018.10.049","volume":"28","author":"JD Kumar","year":"2018","unstructured":"Kumar JD, Zanderigo F, Prabhakaran J, Rubin-Falcone H, Parsey RV, Mann JJ. In vivo evaluation of [11C] TMI, a COX-2 selective PET tracer, in baboons. Bioorg Med Chem Lett. 2018;28(23\u201324):3592\u20135.","journal-title":"Bioorg Med Chem Lett"},{"issue":"6","key":"924_CR11","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1080\/13543776.2019.1623880","volume":"29","author":"SMI Mahboubi Rabbani","year":"2019","unstructured":"Mahboubi Rabbani SMI, Zarghi A. Selective COX-2 inhibitors as anticancer agents: a patent review (2014\u20132018). Expert Opin Ther Pat. 2019;29(6):407\u201327.","journal-title":"Expert Opin Ther Pat"},{"issue":"5","key":"924_CR12","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/j.1445-5994.2006.01056.x","volume":"36","author":"M Hermann","year":"2006","unstructured":"Hermann M, Ruschitzka F. Coxibs, non-steroidal anti-inflammatory drugs and cardiovascular risk. Intern Med J. 2006;36(5):308\u201319.","journal-title":"Intern Med J"},{"issue":"16","key":"924_CR13","doi-asserted-by":"publisher","first-page":"5855","DOI":"10.1016\/j.bmc.2010.06.094","volume":"18","author":"A Zarghi","year":"2010","unstructured":"Zarghi A, Ghodsi R. Design, synthesis, and biological evaluation of ketoprofen analogs as potent cyclooxygenase-2 inhibitors. Bioorg Med Chem. 2010;18(16):5855\u201360.","journal-title":"Bioorg Med Chem"},{"issue":"2_suppl","key":"924_CR14","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1177\/107327480200902S04","volume":"9","author":"AT Koki","year":"2002","unstructured":"Koki AT, Masferrer JL. Celecoxib: a specific COX-2 inhibitor with anticancer properties. Cancer Control. 2002;9(2_suppl):28\u201335.","journal-title":"Cancer Control"},{"issue":"8","key":"924_CR15","first-page":"2343","volume":"62","author":"N Kundu","year":"2002","unstructured":"Kundu N, Fulton AM. Selective cyclooxygenase (COX)-1 or COX-2 inhibitors control metastatic disease in a murine model of breast cancer. Can Res. 2002;62(8):2343\u20136.","journal-title":"Can Res"},{"issue":"1","key":"924_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-10-464","volume":"10","author":"JD Veltman","year":"2010","unstructured":"Veltman JD, Lambers ME, van Nimwegen M, Hendriks RW, Hoogsteden HC, Aerts JG, et al. COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function. BMC Cancer. 2010;10(1):1\u201313.","journal-title":"BMC Cancer"},{"key":"924_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/6393428","volume":"2020","author":"M Assali","year":"2020","unstructured":"Assali M, Abualhasan M, Sawaftah H, Hawash M, Mousa A. Synthesis, biological activity, and molecular modeling studies of pyrazole and triazole derivatives as selective COX-2 inhibitors. J Chem 2020;2020:1\u201314.","journal-title":"J Chem"},{"key":"924_CR18","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ejphar.2015.01.008","volume":"750","author":"GA El-Achkar","year":"2015","unstructured":"El-Achkar GA, Jouni M, Mrad MF, Hirz T, El Hachem N, Khalaf A, et al. Thiazole derivatives as inhibitors of cyclooxygenases in vitro and in vivo. Eur J Pharmacol. 2015;750:66\u201373.","journal-title":"Eur J Pharmacol"},{"issue":"9","key":"924_CR19","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.3390\/molecules22091507","volume":"22","author":"SD Oniga","year":"2017","unstructured":"Oniga SD, Pacureanu L, Stoica CI, Palage MD, Cr\u0103ciun A, Rusu LR, et al. COX inhibition profile and molecular docking studies of some 2-(trimethoxyphenyl)-thiazoles. Molecules. 2017;22(9):1507.","journal-title":"Molecules"},{"issue":"3","key":"924_CR20","doi-asserted-by":"publisher","first-page":"685","DOI":"10.3390\/molecules23030685","volume":"23","author":"K Liaras","year":"2018","unstructured":"Liaras K, Fesatidou M, Geronikaki A. Thiazoles and thiazolidinones as COX\/LOX inhibitors. Molecules. 2018;23(3):685.","journal-title":"Molecules"},{"issue":"3","key":"924_CR21","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1080\/14756360802519558","volume":"24","author":"RN Sharma","year":"2009","unstructured":"Sharma RN, Xavier FP, Vasu KK, Chaturvedi SC, Pancholi SS. Synthesis of 4-benzyl-1, 3-thiazole derivatives as potential anti-inflammatory agents: an analogue-based drug design approach. J Enzyme Inhib Med Chem. 2009;24(3):890\u20137.","journal-title":"J Enzyme Inhib Med Chem"},{"key":"924_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/1570180819666220819151002","volume":"19","author":"M Hawash","year":"2022","unstructured":"Hawash M, Jaradat N, Abualhasan M, Qneibi M, Rifai H, Saqfelhait T, et al. Evaluation of cytotoxic, COX inhibitory, and antimicrobial activities of novel isoxazole-carboxamide derivatives. Lett Drug Design Discovery. 2022;19:1.","journal-title":"Lett Drug Design Discovery."},{"issue":"12","key":"924_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13205-022-03408-8","volume":"12","author":"M Hawash","year":"2022","unstructured":"Hawash M, Jaradat N, Abualhasan M, Qaoud MT, Joudeh Y, Jaber Z, et al. Molecular docking studies and biological evaluation of isoxazole-carboxamide derivatives as COX inhibitors and antimicrobial agents. 3 Biotech. 2022;12(12):1\u201316.","journal-title":"3 Biotech."},{"key":"924_CR24","doi-asserted-by":"crossref","unstructured":"Eid AM, Hawash M, Amer J, Jarrar A, Qadri S, Alnimer I, et al. Synthesis and biological evaluation of novel isoxazole-amide analogues as anticancer and antioxidant agents. BioMed Res Int 2021;2021.","DOI":"10.1155\/2021\/6633297"},{"issue":"1","key":"924_CR25","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1515\/chem-2021-0078","volume":"19","author":"M Hawash","year":"2021","unstructured":"Hawash M, Jaradat N, Abualhasan M, Amer J, Levent S, Issa S, et al. Synthesis, chemo-informatics, and anticancer evaluation of fluorophenyl-isoxazole derivatives. Open Chem. 2021;19(1):855\u201363.","journal-title":"Open Chem"},{"issue":"1","key":"924_CR26","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1515\/hc-2020-0134","volume":"27","author":"M Hawash","year":"2021","unstructured":"Hawash M, Jaradat N, Bawwab N, Salem K, Arafat H, Hajyousef Y, et al. Design, synthesis, and biological evaluation of phenyl-isoxazole-carboxamide derivatives as anticancer agents. Heterocycl Commun. 2021;27(1):133\u201341.","journal-title":"Heterocycl Commun"},{"issue":"1","key":"924_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13065-020-00706-1","volume":"14","author":"M Hawash","year":"2020","unstructured":"Hawash M, Jaradat N, Hameedi S, Mousa A. Design, synthesis and biological evaluation of novel benzodioxole derivatives as COX inhibitors and cytotoxic agents. BMC Chemistry. 2020;14(1):1\u20139.","journal-title":"BMC Chemistry"},{"issue":"5","key":"924_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/cbdv.202001037","volume":"18","author":"M Hawash","year":"2021","unstructured":"Hawash M, Kahraman DC, Cetin-Atalay R, Baytas SN. Induction of apoptosis in hepatocellular carcinoma cell lines by novel indolylacrylamide derivatives: synthesis and biological evaluation. Chem Biodivers. 2021;18(5): e2001037.","journal-title":"Chem Biodivers"},{"key":"924_CR29","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejmech.2017.02.002","volume":"129","author":"MM Hawash","year":"2017","unstructured":"Hawash MM, Kahraman DC, Eren F, Cetin Atalay R, Baytas SN. Synthesis and biological evaluation of novel pyrazolic chalcone derivatives as novel hepatocellular carcinoma therapeutics. Eur J Med Chem. 2017;129:12\u201326.","journal-title":"Eur J Med Chem"},{"issue":"10","key":"924_CR30","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1039\/D1MD00202C","volume":"12","author":"S Kumar","year":"2021","unstructured":"Kumar S, Gupta Y, Zak SE, Upadhyay C, Sharma N, Herbert AS, et al. A novel compound active against SARS-CoV-2 targeting uridylate-specific endoribonuclease (NendoU\/NSP15): in silico and in vitro investigations. RSC Med Chem. 2021;12(10):1757\u201364.","journal-title":"RSC Med Chem"},{"key":"924_CR31","unstructured":"Release, S. 4: Schr\u00f6dinger Suite 2017-4 Protein PreparationWizard; Epik, Schr\u00f6dinger, LLC.: New York, NY, USA; Impact Schr\u00f6dinger LLC.: New York, NY, USA, 2017."},{"issue":"21","key":"924_CR32","doi-asserted-by":"publisher","first-page":"6177","DOI":"10.1021\/jm051256o","volume":"49","author":"RA Friesner","year":"2006","unstructured":"Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, Halgren TA, et al. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein\u2212 ligand complexes. J Med Chem. 2006;49(21):6177\u201396.","journal-title":"J Med Chem"},{"issue":"W1","key":"924_CR33","doi-asserted-by":"publisher","first-page":"W530","DOI":"10.1093\/nar\/gkab294","volume":"49","author":"MF Adasme","year":"2021","unstructured":"Adasme MF, Linnemann KL, Bolz SN, Kaiser F, Salentin S, Haupt VJ, et al. PLIP 2021: expanding the scope of the protein\u2013ligand interaction profiler to DNA and RNA. Nucleic Acids Res. 2021;49(W1):W530\u20134.","journal-title":"Nucleic Acids Res"},{"key":"924_CR34","unstructured":"Schrodinger L. The PyMOL molecular graphics system. Version. 2010;1(5):0."},{"issue":"5","key":"924_CR35","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1517\/17460441.2015.1032936","volume":"10","author":"S Genheden","year":"2015","unstructured":"Genheden S, Ryde U. The MM\/PBSA and MM\/GBSA methods to estimate ligand-binding affinities. Expert Opin Drug Discov. 2015;10(5):449\u201361.","journal-title":"Expert Opin Drug Discov"},{"key":"924_CR36","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jtbi.2013.05.014","volume":"334","author":"SK Tripathi","year":"2013","unstructured":"Tripathi SK, Muttineni R, Singh SK. Extra precision docking, free energy calculation and molecular dynamics simulation studies of CDK2 inhibitors. J Theor Biol. 2013;334:87\u2013100.","journal-title":"J Theor Biol"},{"issue":"4\u20135","key":"924_CR37","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/0009-2614(92)85807-M","volume":"197","author":"PM Gill","year":"1992","unstructured":"Gill PM, Johnson BG, Pople JA, Frisch MJ. The performance of the Becke\u2014Lee\u2014Yang\u2014Parr (B\u2014LYP) density functional theory with various basis sets. Chem Phys Lett. 1992;197(4\u20135):499\u2013505.","journal-title":"Chem Phys Lett"},{"issue":"45","key":"924_CR38","doi-asserted-by":"publisher","first-page":"11623","DOI":"10.1021\/j100096a001","volume":"98","author":"PJ Stephens","year":"1994","unstructured":"Stephens PJ, Devlin FJ, Chabalowski CF, Frisch MJ. Ab initio calculation of vibrational absorption and circular dichroism spectra using density functional force fields. J Phys Chem. 1994;98(45):11623\u20137.","journal-title":"J Phys Chem"},{"key":"924_CR39","doi-asserted-by":"publisher","first-page":"5648","DOI":"10.1063\/1.464913","volume":"98","author":"A Becke","year":"1993","unstructured":"Becke A. Density-functional thermochemistry. III. The role of exact exchange. J Chem Phys. 1993;98:5648\u201352.","journal-title":"J Chem Phys"},{"issue":"20","key":"924_CR40","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1021\/jp0225774","volume":"107","author":"C-G Zhan","year":"2003","unstructured":"Zhan C-G, Nichols JA, Dixon DA. Ionization potential, electron affinity, electronegativity, hardness, and electron excitation energy: molecular properties from density functional theory orbital energies. J Phys Chem A. 2003;107(20):4184\u201395.","journal-title":"J Phys Chem A"},{"issue":"12","key":"924_CR41","doi-asserted-by":"publisher","first-page":"3523","DOI":"10.1016\/j.bmcl.2013.04.039","volume":"23","author":"Y Zheng","year":"2013","unstructured":"Zheng Y, Zheng M, Ling X, Liu Y, Xue Y, An L, et al. Design, synthesis, quantum chemical studies and biological activity evaluation of pyrazole\u2013benzimidazole derivatives as potent Aurora A\/B kinase inhibitors. Bioorg Med Chem Lett. 2013;23(12):3523\u201330.","journal-title":"Bioorg Med Chem Lett"},{"issue":"18","key":"924_CR42","doi-asserted-by":"publisher","first-page":"7306","DOI":"10.1080\/07391102.2020.1808075","volume":"39","author":"AK Maurya","year":"2021","unstructured":"Maurya AK, Mishra N. In silico validation of coumarin derivatives as potential inhibitors against main protease, NSP10\/NSP16-methyltransferase, phosphatase and endoribonuclease of SARS CoV-2. J Biomol Struct Dyn. 2021;39(18):7306\u201321.","journal-title":"J Biomol Struct Dyn"},{"key":"924_CR43","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1093\/jnci\/83.11.757","volume":"83","author":"A Monks","year":"1991","unstructured":"Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, et al. Feasibility of a high-flux anticancer drug screen utilizing a diverse panel of human tumor cell lines in culture. J Natl Cancer Inst. 1991;83:757\u201366.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"924_CR44","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/md19010012","volume":"19","author":"T Chen","year":"2020","unstructured":"Chen T, Huang Y, Hong J, Wei X, Zeng F, Li J, et al. Preparation, COX-2 inhibition and anticancer activity of sclerotiorin derivatives. Mar Drugs. 2020;19(1):12.","journal-title":"Mar Drugs"},{"key":"924_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2020.115960","volume":"32","author":"H Abolhasani","year":"2021","unstructured":"Abolhasani H, Zarghi A, Movahhed TK, Abolhasani A, Daraei B, Dastmalchi S. Design, synthesis and biological evaluation of novel indanone containing spiroisoxazoline derivatives with selective COX-2 inhibition as anticancer agents. Bioorg Med Chem. 2021;32: 115960.","journal-title":"Bioorg Med Chem"},{"issue":"8","key":"924_CR46","doi-asserted-by":"publisher","first-page":"15287","DOI":"10.3390\/molecules200815287","volume":"20","author":"MG Badrey","year":"2015","unstructured":"Badrey MG, Abdel-Aziz HM, Gomha SM, Abdalla MM, Mayhoub AS. Design and synthesis of imidazopyrazolopyridines as novel selective COX-2 inhibitors. Molecules. 2015;20(8):15287\u2013303.","journal-title":"Molecules"},{"issue":"7","key":"924_CR47","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1021\/jm0306430","volume":"47","author":"RA Friesner","year":"2004","unstructured":"Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem. 2004;47(7):1739\u201349.","journal-title":"J Med Chem"},{"issue":"4","key":"924_CR48","doi-asserted-by":"publisher","first-page":"525","DOI":"10.3390\/ijms17040525","volume":"17","author":"D Ram\u00edrez","year":"2016","unstructured":"Ram\u00edrez D, Caballero J. Is it reliable to use common molecular docking methods for comparing the binding affinities of enantiomer pairs for their protein target? Int J Mol Sci. 2016;17(4):525.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"924_CR49","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.3390\/molecules23051038","volume":"23","author":"D Ram\u00edrez","year":"2018","unstructured":"Ram\u00edrez D, Caballero J. Is it reliable to take the molecular docking top scoring position as the best solution without considering available structural data? Molecules. 2018;23(5):1038.","journal-title":"Molecules"},{"issue":"1\u20133","key":"924_CR50","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S0166-1280(02)00316-0","volume":"593","author":"J Fang","year":"2002","unstructured":"Fang J, Li J. Quantum chemistry study on the relationship between molecular structure and corrosion inhibition efficiency of amides. J Mol Struct (Thoechem). 2002;593(1\u20133):179\u201385.","journal-title":"J Mol Struct (Thoechem)"}],"container-title":["BMC Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13065-023-00924-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13065-023-00924-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13065-023-00924-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T03:06:38Z","timestamp":1678071998000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcchem.biomedcentral.com\/articles\/10.1186\/s13065-023-00924-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,6]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["924"],"URL":"https:\/\/doi.org\/10.1186\/s13065-023-00924-3","relation":{},"ISSN":["2661-801X"],"issn-type":[{"value":"2661-801X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,6]]},"assertion":[{"value":"28 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11"}}